Persistence Of Clinically Significant Portal Hypertension After Eradication Of Hepatitis C Virus In Patients With Advanced Cirrhosis

Cristina Díez,Juan Berenguer,Luis Ibañez-Samaniego,Elba Llop,Leire Pérez-Latorre,María V Catalina,Víctor Hontañón,María A Jiménez-Sousa,Teresa Aldámiz-Echevarría,Javier Martínez,José Luis Calleja,Agustín Albillos,José M Bellón,Salvador Resino,Juan González-García,Rafael Bañares

CLINICAL INFECTIOUS DISEASES（2020）

引用 22|浏览18

暂无评分

摘要

This prospective study of 34 patients with HCV cirrhosis (17 HIV positive) with baseline clinically significant portal hypertension (CSPH; HVPG >= 10 mmHg) and SVR after DAA therapy showed that disappearance of CSPH (primary endpoint) is a rare event (6/18 patients; 18%), indicating a persistent risk of clinical progression or death.

查看译文

关键词

cirrhosis, direct-acting antiviral agents, eradication, HCV, portal hypertension

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要